Results 81 to 90 of about 9,514 (200)

Current status and research directions in acute myeloid leukemia

Blood Cancer Journal
The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeutic targets and the development of corresponding novel targeted therapies.
Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi   +10 more
doaj   +1 more source

HYPOMETHYLATING AGENTS IN TREATMENT OF MYELODYSPLASTIC SYNDROME

EUREKA: Health Sciences, 2018
Thelkey to the successful treatment of myelodysplastic syndrome is the careful characterization and diagnosis of the disease, which includes clinical, cytogenetic, biological and molecular investigation of individual patients. Today therapeutic approaches to the treatment of such patients are differentiated and depend, first of all, on the subtype of ...
openaire   +2 more sources

Dordaviprone Maintenance After Allogeneic HCT for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm

American Journal of Hematology, Volume 101, Issue 9, Page 2288-2296, September 2026.
ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt, Christopher S. Wichman, Alyssa Bouska, Moataz Ellithi, Michael Haddadin, Javeed Iqbal, James E. Talmadge, Lori J. Maness, Krishna Gundabolu   +8 more
wiley   +1 more source

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML

European Journal of Haematology, EarlyView.
Shira N. Dinner, Justin M. Watts, Jorge E. Cortes, Jay Yang, Maria R. Baer, Gail J. Roboz, Karen W. L. Yee, Antonio Curti, David C. Taussig, Jürgen Krauter, Thomas Prebet, Hua Tian, Aaron D. Sheppard, Pierre Peterlin, Carolyn Grove, Christian Récher, Stéphane de Botton   +16 more
wiley   +1 more source

Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Patients with high‐risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) continue to face a substantial risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), which remains a leading cause of treatment failure.
Cuicui Lyu, Tianle Xie, Yedi Pu, Xianshuang Luan, Xia Xiao, Mingfeng Zhao, Hairong Lyu   +6 more
wiley   +1 more source

High‐density mutation tracks are associated with proton‐beam irradiation patterns in Sorghum bicolor

The Plant Genome, Volume 19, Issue 3, September 2026.
Abstract Induced mutagenesis is a cornerstone of crop functional genomics, yet the extent to which distinct radiation sources reshape the spatial distribution of mutations remains difficult to evaluate in reduced‐representation datasets. Here, we analyze a published genotyping‐by‐sequencing (GBS) panel (192,040 loci) to compare proton‐beam and gamma ...
Ezekiel Ahn, Insuck Baek, Seunghyun Lim, Louis K. Prom, Moon S. Kim, Lyndel W. Meinhardt, Clint Magill   +6 more
wiley   +1 more source

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

Cancer, Volume 132, Issue 16, 15 August 2026.
Abstract Background Nucleophosmin 1‐mutated (NPM1mt) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long‐term outcomes remain suboptimal without clear predictors identified by therapy. Methods In a retrospective analysis, the authors identified 396 patients (18%) with newly diagnosed (ND) NPM1mt AML treated at ...
Aziz Farhat, Georgina El Hajjar, Hagop Kantarjian, Koji Sasaki, Nicholas J. Short, Branko Cuglievan, Sanam Loghavi, Keyur Patel, Alex Bataller, Wei Ying Jen, Musa Yilmaz, Guillermo Montalban‐Bravo, Danielle Hammond, Naveen Pemmaraju, Naval Daver, Farhad Ravandi, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia‐Manero, Courtney D. DiNardo, Ghayas C. Issa   +21 more
wiley   +1 more source

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Experimental Hematology & Oncology
Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis.
Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao, Wenbin Qian   +10 more
doaj   +1 more source

Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study

Blood and Lymphatic Cancer: Targets and Therapy
Na Zhao,1,2,* Lijun Zhu,1,* Xing Hu,1,* Juan Tong,1 Hongfeng Ge,3 Li Ye,4 Xijun Zhu,5 Can Gai,6 Yuhu Feng,7 Lei Zhang,1 Li Wang,1 Guangyu Sun,1 Lei Xue,1 Xiaoyu Zhu,1 Changcheng Zheng1,8 1Department of Hematology, the First ...
Zhao N, Zhu L, Hu X, Tong J, Ge H, Ye L, Zhu X, Gai C, Feng Y, Zhang L, Wang L, Sun G, Xue L, Zhu X, Zheng C   +14 more
doaj  

DNA Hypomethylation Is Not Cell Intrinsically Toxic to Polycomb Repressive Complex 2 Deficient Malignant Peripheral Nerve Sheath Tumors

Genes, Chromosomes and Cancer, Volume 65, Issue 8, August 2026.
ABSTRACT Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas and the most common cause of disease‐associated death for neurofibromatosis type 1 (NF1) patients. In the context of NF1, MPNSTs develop from benign premalignant precursors and the transition to malignancy is typically accompanied by loss of the polycomb ...
Madilyn R. Stahl, Christopher M. Stehn, Zachary J. Seeman, Christopher Faulk, David A. Largaespada   +4 more
wiley   +1 more source